Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 9;3(2):e164.
doi: 10.1097/AS9.0000000000000164. eCollection 2022 Jun.

Limited Effect of Perioperative Systemic Therapy in Patients Selected for Repeat Local Treatment of Recurrent Colorectal Cancer Liver Metastases

Tessa Hellingman  1 , Boris Galjart  2 , Julia J Henneman  1 , Burak Görgec  3 , Okker D Bijlstra  4 , Martijn R Meijerink  5 , Alexander L Vahrmeijer  4 , Dirk J Grünhagen  2 , Hans J van der Vliet  6   7 , Rutger-Jan Swijnenburg  1   3 , Cornelis Verhoef  2 , Geert Kazemier  1
Affiliations

Limited Effect of Perioperative Systemic Therapy in Patients Selected for Repeat Local Treatment of Recurrent Colorectal Cancer Liver Metastases

Tessa Hellingman et al. Ann Surg Open. .

Abstract

Objectives: The aim of this study was to determine the potential benefit of perioperative systemic therapy on overall and progression-free survival after repeat local treatment in patients suffering from recurrent colorectal cancer liver metastasis (CRLM).

Background: The optimal treatment strategy in patients with recurrent CRLM needs to be clarified, in particular for those suffering from early recurrence of CRLM.

Methods: In this multicenter observational cohort study, consecutive patients diagnosed with recurrent CRLM between 2009 and 2019 were retrospectively identified in 4 academic liver surgery centers. Disease-free interval after initial local treatment of CRLM was categorized into recurrence within 6, between 6 and 12, and after 12 months. Perioperative systemic therapy consisted of induction, (neo)adjuvant, or combined regimens. Overall and progression-free survival after repeat local treatment of CRLM were analyzed by multivariable Cox regression analyses, resulting in adjusted hazard ratios (aHRs).

Results: Out of 303 patients included for analysis, 90 patients received perioperative systemic therapy for recurrent CRLM. Favorable overall (aHR, 0.45; 95% confidence interval [CI], 0.26-0.75) and progression-free (aHR, 0.53; 95% CI, 0.35-0.78) survival were observed in patients with a disease-free interval of more than 12 months. No significant difference in overall and progression-free survival was observed in patients receiving perioperative systemic therapy at repeat local treatment of CRLM, stratified for disease-free interval, previous exposure to chemotherapy, and RAS mutation status.

Conclusions: No benefit of perioperative systemic therapy was observed in overall and progression-free survival after repeat local treatment of recurrent CRLM.

Keywords: prognostic factor; recurrence; survival analysis; treatment strategy.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Overall (A) and progression-free (B) survival curves after repeat local treatment of recurrent CRLM.
FIGURE 2.
FIGURE 2.
Overall survival curves after repeat local treatment of recurrent CRLM with or without perioperative systemic therapy, stratified by disease-free interval (DFI) of less than 6 months (A), 6 to 12 months (B), and more than 12 months (C).
FIGURE 3.
FIGURE 3.
Progression-free survival curves after repeat local treatment of recurrent CRLM with or without perioperative systemic therapy, stratified by disease-free interval (DFI) of less than 6 months (A), 6 to 12 months (B), and more than 12 months (C).
See this image and copyright information in PMC

References

    1. World Health Organization. WHO Factsheet Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed February 3, 2022.
    1. Manfredi S, Lepage C, Hatem C, et al. . Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–259. - PMC - PubMed
    1. Leporrier J, Maurel J, Chiche L, et al. . A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465–474. - PubMed
    1. Abdalla EK, Vauthey JN, Ellis LM, et al. . Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–825; discussion 825–827. - PMC - PubMed
    1. Tanis E, Nordlinger B, Mauer M, et al. . Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer. 2014;50:912–919. - PubMed